期刊
ONCOTARGET
卷 1, 期 1, 页码 22-33出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.105
关键词
Myeloma; CKS1B; ERK1/2; STAT3; drug resistance
资金
- National Institutes of Health [RO1 CA115399]
- University of Utah
- Multiple Myeloma Research Foundation
- NATIONAL CANCER INSTITUTE [R01CA152105, R01CA115399] Funding Source: NIH RePORTER
Here we demonstrate the crucial role of CKS1B in multiple myeloma (MM) progression and define CKS1B-mediated SKP2/p27(Kip1)-independent down-stream signaling pathways. Forced-expression of CKS1B in MM cells increased cell multidrug-resistance. CKS1B activates STAT3 and MEK/ERK pathways. In contrast, SKP2 knockdown or p27(Kip1) over-expression resulted in activation of the STAT3 and MEK/ERK pathways. Further investigations showed that BCL2 is a downstream target of MEK/ERK signaling. Stimulation of STAT3 and MEK/ERK signaling pathways partially abrogated CKS1B knockdown induced MM cell death and growth inhibition. Targeting STAT3 and MEK/ERK signaling pathways by specific inhibitors induced significant MM cell death and growth inhibition in CKS1B-overexpressing MM cells and their combinations resulted in synergy. Thus, our findings provide a rationale for targeting STAT3 and MEK/ERK/BCL2 signaling in aggressive CKS1B-overexpressing MM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据